Skip to main content
. Author manuscript; available in PMC: 2020 Oct 12.
Published in final edited form as: Ear Nose Throat J. 2017 Jul;96(7):E12–E18. doi: 10.1177/014556131709600703

Table 3:

Progression Free Survival and Overall Survival

Progression free survival Overall survival
Univariable Adjusted Univariable Adjusted
HR (95%CI) p-val HR (95%CI) p-val HR (95%CI) p-val HR (95%CI) p-val
ECE 2.48(0.78–7.94) 0.13 1.37(0.39–4.87) 0.63 1.36(0.62–2.96) 0.44 0.98(0.40–2.37) 0.96
3+ positive LNs 5.33(1.76–16.20) 0.003 3.65(1.09–12.31) 0.036 3.05(1.36–6.89) 0.007 2.70(1.13–6.43) 0.025
Largest LN (per 1cm increase) 1.25(0.99–1.56) 0.059 1.08(0.81–1.43) 0.6 1.16(0.98–1.37) 0.087 1.09(0.89–1.31) 0.44
Positive margin 0.98(0.21–4.46) 0.98 0.91(0.19–4.26) 0.9 2.82(0.99–8.01) 0.052 2.90(0.98–8.60) 0.055
Chemotherapy 3.48(1.21–9.98) 0.021 2.23(0.73–6.83) 0.16 1.63(0.70–3.75) 0.26 1.15(0.49–2.75) 0.74